WT1 and neoplasm: Recently, in a ranking of 75 tumor antigens based on characteristics such as therapeutic function, immunogenicity, oncogenicity, and specificity, MUC1 received the second-best rating (after WT1), underlining its potential for medical research and vaccine development [166].